Literature DB >> 23622369

Congenital myasthenic syndromes.

Bruno Eymard1, Daniel Hantaï, Brigitte Estournet.   

Abstract

Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders caused by genetic defects affecting neuromuscular transmission and leading to muscle weakness accentuated by exertion. The characterization of CMS comprises two complementary steps: establishing the diagnosis and identifying the pathophysiological type of CMS. The combination of clinical, electrophysiological, and morphological studies allows the physician to refer a given CMS to mutation(s) in one of the 18 causative genes discovered to date and, in turn, to classify the CMS according to the location of the mutated proteins at the neuromuscular junction into presynaptic compartment, synaptic basal lamina, and postsynaptic compartment CMS. This complete characterization is essential for counseling and therapy of the patient, depending on the molecular background of the respective CMS. Despite comprehensive characterization, the phenotypic expression of one given gene involved is variable, and the etiology of many CMS remains to be discovered.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23622369     DOI: 10.1016/B978-0-444-59565-2.00016-2

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  5 in total

1.  Novel compound heterozygous variants in the GFPT1 gene leading to rare limb-girdle congenital myasthenic syndrome with rimmed vacuoles.

Authors:  Yanyan Ma; Ting Xiong; Guohua Lei; Jiaqi Ding; Rui Yang; Zunbo Li; Jun Guo; Dingguo Shen
Journal:  Neurol Sci       Date:  2021-01-13       Impact factor: 3.307

2.  A Novel Missense Variant in the AGRN Gene; Congenital Myasthenic Syndrome Presenting With Head Drop.

Authors:  Mert Karakaya; Ozge Ceyhan-Birsoy; Alan H Beggs; Haluk Topaloglu
Journal:  J Clin Neuromuscul Dis       Date:  2017-03

3.  Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII α1 Chain.

Authors:  Clare V Logan; Judith Cossins; Pedro M Rodríguez Cruz; David A Parry; Susan Maxwell; Pilar Martínez-Martínez; Joey Riepsaame; Zakia A Abdelhamed; Alice V R Lake; Maria Moran; Stephanie Robb; Gabriel Chow; Caroline Sewry; Philip M Hopkins; Eamonn Sheridan; Sandeep Jayawant; Jacqueline Palace; Colin A Johnson; David Beeson
Journal:  Am J Hum Genet       Date:  2015-11-25       Impact factor: 11.025

4.  Identification of mutations in the MYO9A gene in patients with congenital myasthenic syndrome.

Authors:  Emily O'Connor; Ana Töpf; Juliane S Müller; Daniel Cox; Teresinha Evangelista; Jaume Colomer; Angela Abicht; Jan Senderek; Oswald Hasselmann; Ahmet Yaramis; Steven H Laval; Hanns Lochmüller
Journal:  Brain       Date:  2016-06-03       Impact factor: 13.501

Review 5.  Treating pediatric neuromuscular disorders: The future is now.

Authors:  James J Dowling; Hernan D Gonorazky; Ronald D Cohn; Craig Campbell
Journal:  Am J Med Genet A       Date:  2017-09-10       Impact factor: 2.802

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.